ArticleACS applied materials & interfaces2020
Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles.
Article in ACS applied materials & interfaces, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Apoptotic Bodies: Decoding Their Functional Messages in Physiology and Pathology.Cell biochemistry and function · 2026Review
- Large extracellular vesicles and blebbisomes in cancer: emerging and translational opportunities highlights.Cell communication and signaling : CCS · 2026Review
- The progress and perspective of nanomedicine in modulating the tumor immune microenvironment.Acta pharmaceutica Sinica. B · 2026Review
- Multifunctional vesicles in cancer therapy and theranostics: current advances and future challenges.Journal of nanobiotechnology · 2025Review
- MMP-Sensitive Macrophage-Targeted Coenzyme Q10 Nanomedicine for Rheumatoid Arthritis Treatment.Molecular pharmaceutics · 2025Article
- Environmental protein corona on nanoplastics altered the responses of skin keratinocytes and fibroblast cells to the particles.Journal of hazardous materials · 2025Article
- Therapeutic potential of apoptotic vesicles in modulating inflammation, immune responses, and tissue regeneration.Journal of nanobiotechnology · 2025Review
- Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy.ACS pharmacology & translational science · 2025Review
- A generalized protocol for the induction of M2-like macrophages from mouse and rat bone marrow mononuclear cells.Biology methods & protocols · 2025Article
- Tailoring of apoptotic bodies for diagnostic and therapeutic applications:advances, challenges, and prospects.Journal of translational medicine · 2024Review
- Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy.Journal of hematology & oncology · 2024Review
- Smart Tumor Cell-Derived DNA Nano-Tree Assembly for On-Demand Macrophages Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Advances in biological functions and applications of apoptotic vesicles.Cell communication and signaling : CCS · 2023Review
- Comparison of immunotherapy mediated by apoptotic bodies, microvesicles and exosomes: apoptotic bodies' unique anti-inflammatory potential.Journal of translational medicine · 2023Review
- Apoptotic bodies: bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials.Journal of nanobiotechnology · 2023Review
- Review
- Ghost messages: cell death signals spread.Cell communication and signaling : CCS · 2023Review
- Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms.Frontiers in bioengineering and biotechnology · 2023Review
- Knowledge landscape of tumor-associated macrophage research: A bibliometric and visual analysis.Frontiers in immunology · 2023Article
- Tumor Cell-derived Extracellular Vesicles in Modulating Phenotypes and Immune Functions of Macrophages: Mechanisms and Therapeutic Applications.Journal of Cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Tumor-associated macrophages (TAMs), a major player in the tumor microenvironment, were recently recognized as a potential therapeutic target. To date, very few anticancer drugs or drug-delivery systems were designed to target the TAMs. Inspired by the "eat me" signal, phosphatidylserine (PS), mediated phagocytic clearance of apoptotic bodies, in this study, the matrix metalloproteinase 2 (MMP2)-sensitive PS-modified nanoparticles were developed. In the design, the PS is externalized to the nanoparticles' surface only when the nanoparticles reach the MMP2-overexpressing tumor site, allowing for the TAM-specific phagocytosis. The nanoparticles' excellent macrophage/TAM selectivity was observed in various biological models, including various cell lines, coculture cells, coculture cell spheroids, zebrafish, and tumor-bearing mice. The nanoparticles' TAM specificity remarkably enhanced the TAM depletion capability of the loaded model drug, dasatinib, resulting in the improved anticancer activity. The MMP2-sensitive apoptotic body-mimicking nanoparticles might be a promising delivery tool for TAM-centered cancer diagnoses and treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.